logo
Gen Z's ‘Main Character Energy' Is Running Low, According to New Survey on Mental Well-Being

Gen Z's ‘Main Character Energy' Is Running Low, According to New Survey on Mental Well-Being

Yahoo4 days ago

Many Zoomers Turn to Doomscrolling or Retail Therapy to Cope With Mental Overload; But Some are "Touching Grass"
BOULDER, Colo., June 24, 2025--(BUSINESS WIRE)--As college students might say: the "vibes are off" across the country. A staggering 94% of Americans say they sometimes feel mentally overwhelmed, and the crisis cuts deep for Gen Z (ages 18-28) at 97%. A new survey conducted online by The Harris Poll for Naropa University, a leader in mindfulness education and one of Colorado's top educators of mental health counselors, paints a sobering picture. Many Gen Z (i.e., Zoomers) see themselves as helpers, are emotionally overloaded and unsure how to find relief.
More than two-thirds (68%) of Zoomers agree that they often put other people's emotional needs ahead of their own, and 61% report that they don't know where to turn when they feel emotionally overwhelmed. While more than 80% of Gen Z are on social media, it may not be able to deliver the support they need.
"We commissioned this survey to better understand how people, especially younger generations, emotionally navigate in today's world," said Charles G. Lief, President of Naropa University. "The mental health issues experienced today require fresh approaches to how mental health professionals are trained. That includes recognizing and anticipating the very real risk of professional burnout experienced by therapists, teachers, first responders and others in the helping professions."
A Social Media Paradox: Mental Health Trends Aren't Enough
Starkly compared to a minority of Gen X ages 45-60 (43%) and Baby Boomers ages 61-79 (18%), a majority of Gen Z and Millennials ages 29-44 (63% each) agree they often find mental health information on social media (e.g., TikTok, YouTube, Instagram). Both generations feel like the information is falling short, with 58% of Gen Z and 61% of Millennials agreeing that finding self-care tips online is as helpful as putting a band-aid on a broken bone.
"Gen Zers are emotionally intelligent and aware, but they are stressed," said Azara Santiago-Rivera, Ph.D., Dean of Graduate Psychology at Naropa University. "Gen Zers are open to receiving mental health services and are proactive in seeking such services, including online services. That openness has led to increased demand for services. Our findings show a generation hungry for deeper, more meaningful self-care than the superficial tips they find online."
What Gen Z Coping Looks Like
Gen Zers report some of the ways they are coping with being mentally overwhelmed include:
29% doomscroll—more than any other generation (17% Millennials, 6% Gen X and 2% Boomers);
47% binge-watch TV;
27% use retail therapy; and
64% listen to music
Yet, 31% report touching grass (i.e. engaging with the real world) as a coping tactic, more than any other generation (24% Millennials, 16% Gen X and 15% Boomers). Nearly a third (31%) of Gen Z report going off the grid (i.e.., taking a break from technology/social media) to deal. "These are insightful techniques," remarked Santiago-Rivera, "that can open people up to a more formal introduction of mindfulness and other contemplative tools to break out of the mental overload which is negatively affecting anyone seeking a level of relief and healing."
Zoomers Are Running on Empty, Some Feel Like NPCs
Gen Z are less likely than Millennials to report full energy levels when thinking about the state of the world. Imagining themselves as characters in a video game, only 19% describe their energy levels as full, compared to 26% of Millennials. Nearly one in 10 (8%) of Gen Z say they feel like an NPC (non-playable character) when thinking about the state of the world, perhaps indicating growing disassociation and nihilism.
Survey Method
This survey was conducted online within the United States by The Harris Poll on behalf of Naropa University from May 6-8, 2025, among 2,085 adults ages 18+, among whom 391 are Gen Z (ages 18-28). The sampling precision of Harris online polls is measured by using a Bayesian credible interval. For this study, the sample data is accurate to within +/- 2.5 percentage points using a 95% confidence level.
Email the contact information below for more information on the survey or additional generational data. Gen Z data can be found here. To learn about Naropa's contemplative education programs and approach to mindfulness, visit naropa.edu/academics.
About Naropa University
Naropa University, nestled in Boulder, Colorado, was established in 1974 by Tibetan Buddhist teacher Chögyam Trungpa Rinpoche. Drawing its name and inspiration from the teachings of the 11th-century Indian Buddhist sage Naropa, this private university stands out distinctly among America's higher education landscape in its effort to integrate eastern wisdom with traditional western scholarship. Recognized as the pioneering force behind contemplative higher education and the start of the modern mindfulness movement, Naropa University is the sole institution to integrate a university-wide contemplative pedagogical approach. At Naropa, education transcends the ordinary; the institution embraces the entirety of its students—mind, body and spirit—augmenting traditional methodologies with practices like meditation. Since receiving its accreditation in 1986, Naropa University consistently upholds the exacting standards for quality and accountability set by the Higher Learning Commission (HLC). Learn more at naropa.edu.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250624434731/en/
Contacts
Media Contact Molly SposatoGrasslands: A Journalism-Minded AgencyMolly@MyGrasslands.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit
Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit

Business Wire

timea day ago

  • Business Wire

Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit

BANGKOK--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2025 Invisalign ® Asia Pacific ('APAC') Summit held in Bangkok, Thailand, June 5 – 7, 2025. 'With more than 3 million Invisalign smiles across Asia Pacific, we know that this region sees some of the toughest clinical challenges in the field of dentistry,' said David Carr, Align executive vice president and managing director, APAC. 'The 2025 Invisalign Asia Pacific Summit underscores the importance of continued innovation and education. We are committed to working in partnership with doctors across the region in developing Invisalign treatment protocols that can help them transform smiles and change lives for even more patients.' Over three days, more than 2,000 doctors, practice team members, partners, and Align staff from across the region came together to explore the latest innovations in digital orthodontics and restorative dentistry. The summit featured over 60 expert speakers and more than 50 immersive breakout lectures and hands-on workshops, all designed to help doctors elevate clinical outcomes, streamline workflows, and grow their practices. Key topics covered include kids and teen, complex treatments, comprehensive dentistry and practice growth. 'This meeting provided us with a platform to connect with doctors across the full Asia Pacific region, encourage ongoing learning and sharing and showcase how our global innovations can support doctors in this market,' said Gigi Tsui, Align senior director, clinical, APAC. 'As we celebrate 20 million Invisalign smiles globally, including 3 million Invisalign smiles across the Asia Pacific region, it's critical that we continue to engage doctors for feedback and insights. This is fundamental to developing new innovations that meet the unique needs of doctors and patients across this region.' Attendees explored new developments across multiple interactive zones in the Innovation Hub, including: Kids and Teens: Featuring Invisalign First™, Invisalign® Palatal Expander System, and Invisalign® System with mandibular advancement featuring occlusal blocks ('MAOB'). ClinCheck® signature experience: Highlighting the 1-page Rx form (Flex Rx), preference templates, and ClinCheck ® Live Update. Comprehensive Dentistry: Showcasing iTero Lumina™ Pro dental imaging system, iTero™ intraoral scanner, Invisalign Smile Architect™, and Invisalign® Smile Video. Consumer & Branding: Demonstrating branding and tools to help doctors raise awareness of digital treatment options among patients of all ages. Clinical Excellence: Sharing clinical tools, evidence-based resources, education and insights available to doctors and staff. The summit also featured a Women Leadership session and provider recognition and lifetime achievement awardees. In addition to the core Asia Pacific Invisalign Summit, over 300 delegates across 78 universities also attended the Align APAC University Forum hosted at the renowned Chulalongkorn University in Bangkok. The forum served as a dynamic platform for cross-border collaboration and meaningful dialogue on how Align's evidence-based approach and cutting-edge innovations complements academic excellence and clinical training. Key highlights included keynote presentations by industry experts, interactive case-based discussions, resident showcases, and panels on integrating aligner therapy into university curriculum. The event also celebrated academic excellence with the APAC Case Challenge and Align research awards for APAC, while fostering peer-to-peer collaboration and inspiring the next generation of orthodontic leaders. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

Chemed To Report Second-Quarter 2025 Earnings July 29, 2025
Chemed To Report Second-Quarter 2025 Earnings July 29, 2025

Business Wire

timea day ago

  • Business Wire

Chemed To Report Second-Quarter 2025 Earnings July 29, 2025

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2025, on Tuesday, July 29, 2025, following the close of trading on the New York Stock Exchange. Chemed also announced developments related to second quarter earnings and full year 2025 guidance. In prior public statements, management discussed the possibility that the VITAS subsidiary could have an aggregate Medicare Cap billing limitation (Medicare Cap) related to its Florida consolidated program, excluding Tallahassee. However, as of the most recent quarterly earnings update, VITAS internal projections showed that the Florida consolidated program would end the 2025 government fiscal year ending on September 30, 2025 (2025 Cap Year) with a Medicare Cap cushion. Actual Medicare admissions in both April and May 2025 in Florida were weaker than anticipated and lower than VITAS' internal projections. As a result, VITAS now projects a Medicare Cap revenue limitation for the 2025 Cap Year of $18 million to $25 million related to the Florida consolidated program, excluding Tallahassee. The above projection includes actual results through May. Actual June results, which show better admissions than projected through the first half of the month, and actual results in the third quarter could have a significant impact on this projection. Previous guidance for 2025 earnings did not include any Florida Medicare Cap. The source of the Medicare Cap in the Florida consolidated program relates to two factors. The first factor is the 'community access' program. While community access has provided for a higher-than-average ADC growth rate and revenue growth rate at VITAS over the past two years, it adds pressure to the Medicare Cap due to patients accessing hospice care earlier in their disease trajectory. The second factor is the rate differential between the nationally determined increase in the Medicare Cap per admission and the actual reimbursement increase in our Florida consolidated programs, excluding Tallahassee, for the 2025 Cap Year. Specifically, the Medicare Cap per admission amount increased 2.9% while the Florida consolidated program reimbursement increase was 5.2%. VITAS estimates this rate differential will negatively impact the Florida consolidated program's Medicare Cap calculation by approximately $25 million for the 2025 government fiscal year, accounting for most, if not all, of the total revenue limitation discussed above. On June 20, 2025, the State of Florida announced that VITAS has received a Certificate of Need (CON) to begin operating in Pinellas County, Florida. Pinellas is the most densely populated county in Florida and has a hospice utilization rate below the state average. There were approximately 8,600 Medicare admissions to existing hospice providers in Pinellas County in 2024. Entering Pinellas County represents a significant opportunity for VITAS in 2026 and beyond for both overall growth and Medicare Cap mitigation. Based on the new start locations in Florida, primarily Marion County and Pinellas County, combined with operational changes currently being made in the Florida programs, management expects not to have any significant level of Medicare Cap revenue limitation in our Florida consolidated program for the 2026 fiscal year. This expectation assumes that the rate differential discussed above does not recur for the 2026 Cap Year. In the event that the rate differential does recur, VITAS will respond with further mitigation strategies at the outset of the 2026 Cap Year. While less financially significant than the VITAS Medicare Cap situation, during the second quarter of 2025, Roto-Rooter began to experience unexpected weakness in its residential business' demand compared to internal projections. This weakness represents a break from the trends experienced in the first quarter of 2025. Preliminary results for commercial demand in the second quarter of 2025 continue to reflect improved trends but not enough to offset the lower residential demand. Management is in the process of analyzing second quarter performance and the impact of these developments on second quarter results and on full-year 2025 guidance. A full discussion of the analysis will be included with our second quarter 2025 release and related investor conference call. Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, July 30, 2025, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed's website, Investor Relations Home | Chemed Corporation or the hosting website Participants may also register via teleconference at: Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time. A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed's website. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation ( operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed's operations, including Medicare Cap and Medicare reimbursement rates, Chemed's estimates of the effect of Medicare Cap on VITAS' revenues and future prospects, Chemed's expectations regarding VITAS' patient mix, VITAS's future prospects in Pinellas County, FL and Chemed's expectations regarding demand for Roter-Rooter's services. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed's control. Chemed's actual results and financial condition may differ materially from those indicated in the forward-looking statements included in this press release, including as a result of the risks described above and those described in the Chemed's Annual Report on Form 10-K for the year ended December 31, 2024 and in its Quarterly Reports filed in 2025. Any forward-looking statement made by Chemed in this press release are based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

PRD Therapeutics宣布啟動PRD001的首例人體研究
PRD Therapeutics宣布啟動PRD001的首例人體研究

Business Wire

timea day ago

  • Business Wire

PRD Therapeutics宣布啟動PRD001的首例人體研究

東京--(BUSINESS WIRE)--(美國商業資訊)-- PRD Therapeutics, Inc.是一家臨床階段公司,專注于開發靶向純合子家族性高膽固醇血症(HoFH)和代謝功能障礙相關脂肪性肝病(MASH/MASLD)的新型脂質代謝調節劑。該公司今日宣布,近期已啟動PRD001的首例人體(FIH)臨床試驗給藥。PRD001是一款同類首創的SOAT2(原稱ACAT2)選擇性抑制劑。 PRD Therapeutics執行長兼共同創辦人Kanji Hosoda博士表示:「我們很高興啟動PRD001臨床試驗的給藥。此前已展開過多項針對SOAT1/2雙重抑制劑或SOAT1選擇性抑制劑的臨床試驗,但這是第一個針對SOAT2選擇性抑制劑的臨床試驗。多項關於SOAT1或2基因敲除小鼠的研究結果已發表,顯示僅敲除或抑制SOAT2對證明安全性和有效性至關重要。PRD001是全球第一個且唯一的SOAT2選擇性抑制劑,可望也在人體中展現安全性和有效性。我們的臨床前動物模型(LDL-R KO小鼠;HoFH模型,以及高脂飲食誘導的MASH模型小鼠)顯示,PRD001可降低血液和肝臟脂質水準,抑制脂肪肝和動脈粥樣硬化的進展,且無不良事件。對於LDL受體活性缺失或極低的HoFH病患,PRD001可望成為同類第一個有效且安全的口服療法。」 該FIH 1期研究旨在評估PRD001在成年健康志願者中的安全性、耐受性、藥物動力學及早期療效跡象(LDL-C降低效應,以及使用MRI-PDFF檢測的肝臟脂肪量化值)。更多資訊可在 NCT07034183 查詢。 關於PRD001 PRD001是同類首創的口服小分子SOAT2選擇性抑制劑。它透過單一藥物獨特控制脂質代謝的三大關鍵途徑:肝臟膽固醇合成、小腸膽固醇吸收以及血液LDL-C攝取,從而強效降低血液LDL-C水準,且不依賴LDL受體。 本研發專案由日本醫療研究開發機構(AMED)透過 製藥初創企業生態系統強化計畫 提供支援(專案名稱:「同類首創口服脂質代謝調節劑PRD001的開發及脂質代謝紊亂的POC驗證」)。 免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store